Osisko Development Reports Underground Sampling Results
79.45 oz/t Au and 6.27 oz/t Ag over 5.5 ft. including 434.09 oz/t Au and 33.65 oz/t Ag over 1.0 ft.
(2,724 g/t Au and 215.12 g/t Ag over 1.68 m including 14,883.2 g/t Au and 1,153 g/t Ag over 0.30 m.)
MONTREAL, July 7, 2022 – Osisko Development Corp. (“Osisko Development” or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/osisko-development-corp/) is pleased to announce results from its ongoing underground exploration program on the recently acquired Tintic project and its 100% owned Trixie Mine (“Trixie”), as well as mineral claims covering more than 17,000 acres (including over 14,200 acres of which are patented) located in Central Utah’s historic Tintic Mining District (together with Trixie, the “Tintic Project”).
Summary
- Trixie is one of several gold and base metal targets within the larger Tintic Project. The discovery of the T2 and T4 mineralized structures at Trixie in late 2020 by Tintic Consolidated Metals, LLC (“TCM”) showed gold (“Au”) and silver (“Ag”) grades associated with high sulphidation alteration hosted within quartzites that are capped by impermeable shales and volcanics.
- Current underground mining activities at Trixie are directed by the exploration sampling and drilling results.
- Results shown below are derived from 703 samples collected across a total of 183 sites (site ID 783 to 934) near the 625 ft level at Trixie across a total combined strike length of 650 ft. (~200 m). See Figure 1.
- The sample results indicate anomalous gold results throughout the entire sampled area, and along exploration cross-cuts (Figure 1).
- The mineralized structures remain open along strike and at depth and significant potential exists to expand the known mineralization.
- The Company is currently expanding underground developments and utilizing one underground diamond drill rig and one surface reverse circulation rig to aid in the delineation of an initial mineral resource estimate by the end of Q4 2022. Results from this drilling program are pending.
Assay Highlights
- 31.79 oz/t Au and 9.07 oz/t Ag over 4.8 ft. at site 738 (1,089.83 g/t Au and 310.93 g/t Ag over 1.46 m) including
- 76.11 oz/t Au and 21.76 oz/t Ag over 2.0 ft. (2,609.65 g/t Au and 746.22 g/t Ag over 0.61 m)
- 6.07 oz/t Au and 11.02 oz/t Ag over 9.0 ft. at site 742 (208.20 g/t Au and 377.87 g/t Ag over 2.74 m)
- 10.28 oz/t Au and 8.60 oz/t Ag over 6.6 ft. at site 746 (352.56 g/t Au and 294.87 g/t Ag over 2.01 m) including
- 26.28 oz/t Au and 21.01 oz/t Ag over 2.5 ft. (901.03 g/t Au and 720.25 g/t Ag over 0.76 m)
- 9.03 oz/t Au and 9.72 oz/t Ag over 6.7 ft. at site 747 (309.48 g/t Au and 333.35 g/t Ag over 2.04 m)
- 15.31 oz/t Au and 49.43 oz/t Ag over 4.8 ft. at site 787 (525.02 g/t Au and 1,694.76 g/t Ag over 1.46 m) including
- 33.35 oz/t Au and 104.90 oz/t Ag over 2.0 ft. (1,143.35 g/t Au and 3,596.74 g/t Ag over 0.61 m)
- 8.95 oz/t Au and 7.67 oz/t Ag over 16.0 ft. at site 792 (306.97 g/t Au and 262.91 g/t Ag over 4.88 m) including
- 23.28 oz/t Au and 11.03 oz/t Ag over 2.0 ft. (798.05 g/t Au and 378.23 g/t Ag over 0.61 m)
- 12.60 oz/t Au and 22.50 oz/t Ag over 4.0 ft. at site 878 (432.04 g/t Au and 771.44 g/t Ag over 1.22 m)
- 4.62 oz/t Au and 6.95 oz/t Ag over 12.0 ft. at site 889 (158.23 g/t Au and 238.30 g/t Ag over 3.66 m)
- 20.26 oz/t Au and 15.76 oz/t Ag over 6.4 ft. at site 893 (694.50 g/t Au and 540.37 g/t Ag over 1.95 m) including
- 108.57 oz/t Au and 71.60 oz/t Ag over 1.1 ft. (3,722.31 g/t Au and 2,454.88 g/t Ag over 0.34 m)
- 80.85 oz/t Au and 66.20 oz/t Ag over 4.5 ft. at site 896 (2,771.97 g/t Au and 2,269.69 g/t Ag over 1.3716 m) including
- 157.23 oz/t Au and 128.17 oz/t Ag over 2.3 ft. (5,390.78 g/t Au and 4,394.48 g/t Ag over 0.70 m)
- 11.97 oz/t Au and 17.20 oz/t Ag over 5.5 ft. at site 898 (410.31 g/t Au and 589.75 g/t Ag over 1.68 m) including
- 41.72 oz/t Au and 59.72 oz/t Ag over 1.5 ft. (1,430.44 g/t Au and 2,047.51 g/t Ag over 0.46 m)
- 17.70 oz/t Au and 7.11 oz/t Ag over 5.0 ft. at site 910 (606.75 g/t Au and 243.87 g/t Ag over 1.52 m) including
- 51.03 oz/t Au and 13.35 oz/t Ag over 1.0 ft. (1,749.76 g/t Au and 457.69 g/t Ag over 0.30 m)
- 33.61 oz/t Au and 6.25 oz/t Ag over 4.0 ft. at site 911 (1,152.40 g/t Au and 214.18 g/t Ag over 1.22 m) including
- 121.05 oz/t Au and 12.42 oz/t Ag over 1.0 ft. (4,150.15 g/t Au and 425.99 g/t Ag over 0.30 m)
- 79.45 oz/t Au and 6.27 oz/t Ag over 5.5 ft. at site 913 (2,724.03 g/t Au and 215.12 g/t Ag over 1.68 m) including
- 434.09 oz/t Au and 33.65 oz/t Ag over 1.0 ft. (14,883.2 g/t Au and 1,153.72 g/t Ag over 0.30 m)
- 16.63 oz/t Au and 2.49 oz/t Ag over 5.0 ft. at site 914 (570.32 g/t Au and 85.46 g/t Ag over 1.52 m) including
- 26.47 oz/t Au and 3.86 oz/t Ag over 2.0 ft. (907.44 g/t Au and 132.26 g/t Ag over 0.61 m)
A length weighted composite for each face Site ID is shown in Table 1 and individual higher grade samples are also identified within the composite. Samples are collected in feet and assays are reported in g/t Au. Conversions to metric and imperial are rounded to two decimal places.
Chris Lodder, President of Osisko Development commented, “The Trixie underground sampling results from 2020 to present show exceptional continuity of high grades associated with the T2 structure. These 2022 samples along with the historic sampling by TCM, and in combination with the ongoing exploration developments within the present 720 ft strike by 175 ft vertical by 80 ft wide zone gives Osisko Development with a strong base for present mining activity and initial resources estimation. We will continue to use the present shaft / hoist at Trixie but we anticipate to increase access and mining capacity to the 625 ft and lower levels of Trixie through a new underground ramp initiated very recently and expected to reach the 625 ft level in Q1 2023.”
The T2 and T4 mineralized structures are associated with high-sulphidation epithermal mineralization, structurally controlled and hosted within the brittle Tintic Quartzite and capped by the impermeable shales of the Lower Ophir Formation. The T2 structure is 1 to 8 ft. wide (0.3 m to 2.4m) and mineralization consists of native Au, and rare Au-Ag – rich telluride minerals with quartz. The T4 is a mineralized stockwork zone ranging from to 10 to 80 ft. (3 m to 25 m) and located in the hanging wall of the T2 and is comprised of Au-Ag rich mineralization in host rock quartzite with quartz-barite-sulphosalt stockwork veining. Mineralization currently defined over 220 meters (720 feet) in strike and reports consistent multi-ounce gold grades along its entire strike length.
Face Sampling Methodology
As most structures at Trixie are steeply dipping to the east or west, current sampling procedures are designed to sample the structure. Channel samples are collected and do not exceed 3 ft. (1.0 m) in length. The face is washed for safety, and for better identification of mineralization, alteration and structures. The hangingwall and footwall of the structures are marked up on the face and back, samples intervals are marked up and follow lithological contacts.
For further information on Tintic, including additional production details please see the technical report on the Tintic Project, entitled "Technical Report on the Tintic Project, East Tintic Mining District, Utah County, Utah, USA", dated June 10, 2022 (effective date of June 7, 2022), and filed at www.sedar.com under the profile of the Company.
Figure 1: 625 L Map with Select Assay Highlights
Qualified Persons
Per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Maggie Layman, P.Geo. Vice President Exploration of Osisko Development Corp., is a Qualified Person and has prepared, validated, and approved the technical and scientific content of this news release.
Quality Assurance (QA)/Quality Control (QC)
All underground face samples are collected by TCM geologists from each of the active mining faces, with samples transported by the geologists from Trixie to the on-site TCM laboratory located at the Burgin administrative complex. Underground samples are dried, crushed to <10 mm and a 250 g split is taken. The split is pulverized, and a 30 g Fire Assay with gravimetric finish is completed to determine gold and silver grades, reported in oz./short ton and g/t.
The TCM Burgin laboratory is not a certified analytical laboratory, but the facility is managed by a qualified Laboratory Manager with annual auditing by technical staff. Inter-laboratory check assays using ALS Laboratory as a third-party independent analysis of samples is routinely carried out as part of ongoing QA/QC work. Certified OREAS Quality Control (“QC”) standards and blanks are inserted at regular intervals in the sample stream to monitor laboratory performance.
All drill core and exploration samples are dispatched to ALS Laboratory for offsite sample preparation and analysis. Samples are assigned a unique sample ID. All geological and sampling information is entered into Datashed database. Core is sawn in half and half are sampled. Certified standards and blanks inserted into all sample dispatches. Samples are collected by Old Dominion Transportation and dispatched to ALS Laboratory in Reno, NV. Sample submission forms accompany the samples, and digital copies emailed to ALS.
All sample preparation is completed by ALS, including crushing and pulverizing (Prep31) of samples. Analytical assay include gold and silver by fire assay of 50g sample with AAS finish (Au-AA26), over limits by gravimetric analysis (Au-Grav22). Multi element analysis is by four acid digest (ME-MS61). The pulps are returned to TCM and coarse rejects are disposed after 90 days. Assays are reported to TCM, and then loaded into Datashed, QA/QC samples are checked, and assays merged with sample information for future reporting.
Cautionary Statements
The Company cautions that the decision to commence production at Trixie in the form of small scale underground mining and batch vat leaching has been made without the benefit of a feasibility study, or reported mineral resources or mineral reserves, demonstrating economic and technical viability, and, as a result there may be increased uncertainty of achieving any particular level of recovery of material or the cost of such recovery. The Company cautions that historically, such projects have a much higher risk of economic and technical failure. There is no guarantee that production will continue as anticipated or at all or that anticipated production costs will be achieved. The failure to continue production may have a material adverse impact on the Company's ability to generate revenue and cash flow to fund operations. Failure to achieve the anticipated production costs may have a material adverse impact on the Company's cash flow and potential profitability. In continuing current operations at Trixie after closing, the Company will not be basing its decision to continue such operations on a feasibility study, or reported mineral resources or mineral reserves demonstrating economic and technical viability. The Company cautions that mining at Trixie could be suspended at any time.
The Company is subject to the reporting requirements of the applicable Canadian securities laws, and as a result reports information regarding mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in the Tintic Technical Report and this news release, in accordance with Canadian reporting requirements, which are governed by NI 43-101. As such, such information concerning mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in the Tintic Technical Report and this news release, is not comparable to similar information made public by U.S. companies subject to the reporting and disclosure requirements of the SEC.
About Osisko Development Corp.
Osisko Development Corp. is uniquely positioned as a premier gold development company in North America to advance the Cariboo Gold Project and other Canadian, U.S.A. and Mexican properties, with the objective of becoming the next mid-tier gold producer. The Cariboo Gold Project, located in central British Columbia, Canada, is Osisko Development's flagship asset. The considerable exploration potential at depth and along strike distinguishes the Cariboo Gold Project relative to other development assets. Osisko Development's project pipeline is complemented by its interest in the San Antonio gold project, located in Sonora, Mexico and the Trixie gold test mine, located in Utah, U.S.A.
For further information about Osisko Development [(NYSE: ODV; TSX-V:ODV)], please visit www.osiskodevelopment.com or follow us on Twitter @OsiskoDev
Investor Contact:
Jean Francois Lemonde
VP, Investor Relations
Tel: 514-299-4926
In Europe:
Swiss Resource Capital AG
Jochen Staiger
Forward-looking Statements
Certain statements contained in this news release may be deemed "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. These forward‐looking statements, by their nature, require Osisko Development to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward‐looking statements. Forward‐looking statements are not guarantees of performance. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward‐looking statements. Information contained in forward‐looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management's perceptions of historical trends, current conditions and expected future developments, results of further exploration work to define and expand mineral resources, and that the deposit remains open for expansion at depth and down plunge, as well as other considerations that are believed to be appropriate in the circumstances, and any other information herein that is not a historical fact may be "forward looking information". Material assumptions also include, management's perceptions of historical trends, current conditions and expected future developments, results of further exploration work to define or expand any mineral resources, the ability to continue production at its Trixie mine, as well as other considerations that are believed to be appropriate in the circumstances. Osisko Development considers its assumptions to be reasonable based on information currently available, but cautions the reader that their assumptions regarding future events, many of which are beyond the control of Osisko Development, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect Osisko Development and its business. Such risks and uncertainties include, among others, risks relating to capital market conditions, the ability to continue current production, regulatory framework, the ability of exploration activities (including drill results) to accurately predict mineralization; errors in management's geological modelling; the ability of to complete further exploration activities, including drilling; property and stream interests in the Project; the ability of the Company to obtain required approvals; the results of exploration activities; risks relating to exploration, development and mining activities; the global economic climate; metal prices; dilution; environmental risks; and community and non-governmental actions and the responses of relevant governments to the COVID-19 outbreak and the effectiveness of such responses. Readers are urged to consult the disclosure provided under the heading "Risk Factors" in the Company's annual information form for the year ended December 31, 2021, as amended, which has been filed on SEDAR (www.sedar.com) under Osisko Development's issuer profile and on the SEC's EDGAR website (www.sec.gov), for further information regarding the risks and other factors applicable to the exploration results. Although the Company's believes the expectations conveyed by the forward-looking statements are reasonable based on information available at the date of preparation, no assurances can be given as to future results, levels of activity and achievements. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that these forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Table 1: 2022 Length Weighted Assay Composites at Trixie
Imperial
Metric
Site ID
Depth from (ft.)
Depth to (ft.)
Length (ft.)
Au oz/t
Ag oz/t
Depth from (m)
Depth to (m)
Length (m)
Au (g/t)
Ag (g/t)
738
0.0
4.8
4.8
31.79
9.07
0.00
1.46
1.46
1,089.83
310.93
738
including
1.5
3.5
2.0
76.11
21.76
0.46
1.07
0.61
2,609.65
746.22
739
0.0
8.3
8.3
0.97
2.29
0.00
2.53
2.53
33.29
78.47
739
including
3.0
5.7
2.7
1.34
4.41
0.91
1.74
0.82
45.88
151.30
739
and
5.7
6.9
1.2
2.51
4.60
1.74
2.10
0.37
85.92
157.86
740
0.0
4.0
4.0
4.73
5.66
0.00
1.22
1.22
162.22
194.22
740
including
2.3
4.0
1.7
11.13
13.33
0.70
1.22
0.52
381.60
456.97
741
0.0
2.7
2.7
0.43
0.00
0.00
0.82
0.82
14.78
0.01
741
including
1.2
2.4
1.2
0.95
0.00
0.37
0.73
0.37
32.66
0.01
742
0.0
9.0
9.0
6.07
11.02
0.00
2.74
2.74
208.20
377.87
742
including
4.0
7.3
3.3
3.09
6.42
1.22
2.23
1.01
105.98
220.16
742
and
7.3
9.0
1.7
25.99
45.88
2.23
2.74
0.52
890.97
1,573.11
743
0.0
3.7
3.7
4.58
2.04
0.00
1.13
1.13
156.97
70.03
743
including
0.0
1.5
1.5
10.01
5.04
0.00
0.46
0.46
343.03
172.73
744
0.0
6.6
6.6
5.00
2.45
0.00
2.01
2.01
171.39
84.05
744
including
1.5
3.8
2.3
13.87
5.24
0.46
1.16
0.70
475.69
179.60
745
0.0
7.7
7.7
1.32
2.12
0.00
2.35
2.35
45.12
72.86
745
including
4.2
6.7
2.5
3.48
5.50
1.28
2.04
0.76
119.33
188.62
746
0.0
6.6
6.6
10.28
8.60
0.00
2.01
2.01
352.56
294.87
746
including
2.3
4.8
2.5
26.28
21.01
0.70
1.46
0.76
901.03
720.25
747
0.0
6.7
6.7
9.03
9.72
0.00
2.04
2.04
309.48
333.35
747
including
0.0
1.2
1.2
30.54
21.52
0.00
0.37
0.37
1,047.03
737.97
747
and
1.2
2.3
1.1
16.59
29.89
0.37
0.70
0.34
568.84
1,024.73
747
and
2.3
3.3
1.0
1.02
2.85
0.70
1.01
0.30
35.14
97.67
747
and
5.5
6.7
1.2
3.23
1.87
1.68
2.04
0.37
110.78
64.02
748
0.0
5.4
5.4
0.65
1.19
0.00
1.65
1.65
22.12
40.93
748
including
1.9
3.0
1.1
3.13
5.17
0.58
0.91
0.34
107.19
177.21
749
0.0
5.4
5.4
1.26
1.89
0.00
1.65
1.65
43.25
64.78
749
including
2.3
4.4
2.1
2.96
4.54
0.70
1.34
0.64
101.61
155.54
750
0.0
5.0
5.0
1.13
2.91
0.00
1.52
1.52
38.90
99.93
750
including
2.4
3.4
1.0
5.50
14.57
0.73
1.04
0.30
188.41
499.62
751
0.0
6.0
6.0
0.13
0.26
0.00
1.83
1.83
4.29
8.91
751
including
2.8
5.0
2.2
0.27
0.46
0.85
1.52
0.67
9.13
15.75
752
0.0
5.0
5.0
0.13
0.47
0.00
1.52
1.52
4.51
15.96
753
0.0
11.4
11.4
3.02
6.73
0.00
3.47
3.47
103.67
230.61
753
including
2.0
3.5
1.5
0.66
2.42
0.61
1.07
0.46
22.63
82.93
753
and
3.5
5.4
1.9
8.10
19.11
1.07
1.65
0.58
277.65
655.33
753
and
5.4
7.4
2.0
2.25
6.65
1.65
2.26
0.61
77.24
227.91
753
and
7.4
9.2
1.8
0.54
1.69
2.26
2.80
0.55
18.62
58.11
753
and
9.2
10.4
1.2
10.33
16.63
2.80
3.17
0.37
354.13
570.24
754
0.0
4.2
4.2
0.08
0.22
0.00
1.28
1.28
2.73
7.68
755
0.0
3.0
3.0
0.20
0.92
0.00
0.91
0.91
6.85
31.50
755
including
2.3
3.0
0.7
0.73
2.11
0.70
0.91
0.21
24.90
72.40
756
0.0
3.5
3.5
0.10
0.14
0.00
1.07
1.07
3.33
4.91
756
including
1.0
2.0
1.0
0.28
0.26
0.30
0.61
0.30
9.66
8.98
757
No significant assays
758
No significant assays
759
No significant assays
760
No significant assays
761
0.0
3.7
3.7
0.06
0.32
0.00
1.13
1.13
2.02
10.99
761
including
1.7
2.0
0.3
0.43
1.01
0.52
0.61
0.09
14.63
34.65
762
No significant assays
763
No significant assays
764
91.0
111.0
20.0
0.06
0.23
27.74
33.83
6.10
1.91
8.04
764
including
97.0
99.0
2.0
0.52
0.00
29.57
30.18
0.61
17.86
0.01
769
No significant assays
770
No significant assays
771
No significant assays
772
0.0
5.0
5.0
0.09
0.24
0.00
1.52
1.52
3.24
8.08
772
including
2.7
3.5
0.8
0.57
1.37
0.82
1.07
0.24
19.40
46.90
773
0.0
10.4
10.4
0.04
1.76
0.00
3.17
3.17
1.23
60.33
773
including
7.9
9.4
1.5
0.24
10.01
2.41
2.87
0.46
8.26
343.34
774
0.0
8.5
8.5
0.01
0.59
0.00
2.59
2.59
0.51
20.07
774
including
8.0
8.5
0.5
0.07
5.69
2.44
2.59
0.15
2.43
195.17
775
No significant assays
776
No significant assays
777
0.0
8.0
8.0
0.07
0.23
0.00
2.44
2.44
2.50
8.00
777
including
5.0
8.0
3.0
0.18
0.45
1.52
2.44
0.91
6.09
15.58
778
0.0
7.0
7.0
0.31
0.59
0.00
2.13
2.13
10.65
20.22
778
including
0.0
3.4
3.4
0.30
0.00
0.00
1.04
1.04
10.18
0.01
778
and
3.4
5.0
1.6
0.72
2.58
1.04
1.52
0.49
24.64
88.42
779
No significant assays
780
0.0
4.3
4.3
3.26
2.56
0.00
1.31
1.31
111.90
87.77
780
0.0
2.0
2.0
6.99
5.50
0.00
0.61
0.61
239.49
188.69
781
0.0
8.0
8.0
0.55
1.05
0.00
2.44
2.44
18.82
35.96
781
including
3.0
4.0
1.0
4.31
7.86
0.91
1.22
0.30
147.65
269.39
782
0.0
3.0
3.0
1.29
1.84
0.00
0.91
0.91
44.11
63.25
783
0.0
7.5
7.5
0.03
0.24
0.00
2.29
2.29
1.08
8.20
783
including
6.1
7.0
0.9
0.15
1.17
1.86
2.13
0.27
5.14
40.26
784
0.0
3.6
3.6
0.27
3.27
0.00
1.10
1.10
9.22
112.27
784
including
0.0
0.6
0.6
0.35
4.36
0.00
0.18
0.18
11.94
149.52
784
and
0.6
1.6
1.0
0.62
6.04
0.18
0.49
0.30
21.20
207.01
785
0.0
8.1
8.1
0.07
0.56
0.00
2.47
2.47
2.50
19.14
785
including
1.2
4.8
3.6
0.15
0.97
0.37
1.46
1.10
5.25
33.32
786
0.0
3.2
3.2
1.36
5.25
0.00
0.98
0.98
46.74
180.17
786
including
2.4
3.2
0.8
4.19
6.27
0.73
0.98
0.24
143.56
214.94
787
0.0
4.8
4.8
15.31
49.43
0.00
1.46
1.46
525.02
1,694.76
787
including
0.0
0.8
0.8
8.41
32.15
0.00
0.24
0.24
288.38
1,102.30
787
and
0.8
2.8
2.0
33.35
104.90
0.24
0.85
0.61
1,143.35
3,596.74
788
No significant assays
790
0.0
2.5
2.5
4.09
26.72
0.00
0.76
0.76
140.11
916.14
790
including
0.0
1.5
1.5
6.13
40.27
0.00
0.46
0.46
210.11
1,380.78
791
0.0
14.0
14.0
0.61
0.44
0.00
4.27
4.27
20.89
14.99
791
including
2.0
4.0
2.0
3.76
1.92
0.61
1.22
0.61
129.04
65.86
792
0.0
16.0
16.0
8.95
7.67
0.00
4.88
4.88
306.97
262.91
792
including
4.0
6.0
2.0
18.50
23.32
1.22
1.83
0.61
634.42
799.42
792
and
6.0
8.0
2.0
17.32
16.21
1.83
2.44
0.61
593.69
555.85
792
and
10.0
12.0
2.0
4.43
2.95
3.05
3.66
0.61
151.73
101.06
792
and
12.0
14.0
2.0
3.52
0.66
3.66
4.27
0.61
120.84
22.49
792
and
14.0
16.0
2.0
23.28
11.03
4.27
4.88
0.61
798.05
378.23
793
0.0
5.0
5.0
0.44
2.96
0.00
1.52
1.52
15.25
101.41
793
including
0.0
3.5
3.5
0.63
3.39
0.00
1.07
1.07
21.56
116.15
794
No significant assays
795
No significant assays
796
No significant assays
797
No significant assays
798
No significant assays
799
No significant assays
800
No significant assays
801
0.0
6.0
6.0
0.19
0.60
0.00
1.83
1.83
6.55
20.55
801
including
4.0
4.6
0.6
0.52
1.33
1.22
1.40
0.18
17.84
45.43
801
and
5.3
6.0
0.7
0.81
3.70
1.62
1.83
0.21
27.83
126.97
802
0.0
4.9
4.9
0.36
1.72
0.00
1.49
1.49
12.29
58.84
802
including
2.4
4.9
2.5
0.65
3.24
0.73
1.49
0.76
22.33
111.01
803
0.0
5.1
5.1
0.17
3.06
0.00
1.55
1.55
5.81
104.89
805
0.0
6.5
6.5
1.68
0.93
0.00
1.98
1.98
57.66
32.04
805
including
0.0
3.5
3.5
0.34
0.38
0.00
1.07
1.07
11.58
13.12
805
and
3.5
5.5
2.0
4.07
2.07
1.07
1.68
0.61
139.59
71.05
805
and
5.5
6.5
1.0
1.61
0.59
1.68
1.98
0.30
55.06
20.21
806
0.0
6.0
6.0
0.02
0.43
0.00
1.83
1.83
0.54
14.91
806
including
0.0
0.5
0.5
0.09
1.20
0.00
0.15
0.15
3.15
41.02
807
No significant assays
810
No significant assays
811
No significant assays
812
No significant assays
813
No significant assays
814
No significant assays
815
0.0
6.5
6.5
1.36
2.31
0.00
1.98
1.98
46.77
79.13
815
including
3.0
4.5
1.5
0.65
1.42
0.91
1.37
0.46
22.24
48.53
815
and
4.5
6.5
2.0
3.95
6.07
1.37
1.98
0.61
135.31
208.23
816
0.0
5.9
5.9
0.17
1.08
0.00
1.80
1.80
5.76
37.17
816
including
4.9
5.9
1.0
0.47
0.86
1.49
1.80
0.30
16.25
29.45
817
No significant assays
818
No significant assays
819
No significant assays
820
No significant assays
821
0.0
4.0
4.0
0.87
2.77
0.00
1.22
1.22
29.89
94.81
821
including
0.0
2.4
2.4
1.16
2.54
0.00
0.73
0.73
39.76
86.99
821
and
2.4
3.4
1.0
0.68
4.79
0.73
1.04
0.30
23.28
164.31
822
0.0
4.7
4.7
0.23
0.51
0.00
1.43
1.43
7.92
17.37
822
including
0.0
1.0
1.0
1.06
2.25
0.00
0.30
0.30
36.24
77.12
823
No significant assays
824
No significant assays
825
0.0
4.4
4.4
0.08
1.03
0.00
1.34
1.34
2.69
35.23
825
including
2.8
3.8
1.0
0.26
3.16
0.85
1.16
0.30
9.05
108.22
826
0.0
5.7
5.7
0.08
0.60
0.00
1.74
1.74
2.84
20.52
826
including
1.5
3.0
1.5
0.19
1.07
0.46
0.91
0.46
6.58
36.68
827
0.0
4.9
4.9
0.04
0.60
0.00
1.49
1.49
1.28
20.40
828
0.0
8.0
8.0
0.06
0.64
0.00
2.44
2.44
2.12
22.08
828
including
6.0
8.0
2.0
0.25
2.24
1.83
2.44
0.61
8.43
76.83
829
No significant assays
830
No significant assays
831
No significant assays
832
0.0
14.0
14.0
1.30
3.33
0.00
4.27
4.27
44.67
114.18
832
including
0.0
2.0
2.0
0.49
0.20
0.00
0.61
0.61
16.73
6.82
832
and
6.0
8.0
2.0
1.13
11.25
1.83
2.44
0.61
38.66
385.61
832
and
8.0
10.0
2.0
6.54
10.32
2.44
3.05
0.61
224.19
353.74
832
and
10.0
12.0
2.0
0.72
1.38
3.05
3.66
0.61
24.81
47.22
833
0.0
14.0
14.0
0.33
0.70
0.00
4.27
4.27
11.29
24.13
833
including
4.0
6.0
2.0
0.23
0.89
1.22
1.83
0.61
8.02
30.53
833
and
6.0
8.0
2.0
1.50
2.86
1.83
2.44
0.61
51.47
98.08
833
and
12.0
14.0
2.0
0.51
0.33
3.66
4.27
0.61
17.58
11.27
834
No significant assays
835
No significant assays
836
0.0
3.9
3.9
0.03
1.78
0.00
1.19
1.19
0.95
60.88
837
No significant assays
838
0.0
18.0
18.0
0.33
1.57
0.00
5.49
5.49
11.33
53.96
838
including
0.0
3.0
3.0
0.72
3.69
0.00
0.91
0.91
24.85
126.64
838
and
6.0
9.0
3.0
1.07
4.18
1.83
2.74
0.91
36.54
143.16
840
No significant assays
841
No significant assays
842
No significant assays
843
0.0
6.2
6.2
0.04
1.10
0.00
1.89
1.89
1.54
37.82
844
No significant assays
845
0.0
4.5
4.5
0.09
0.39
0.00
1.37
1.37
3.08
13.50
845
including
2.0
4.5
2.5
0.15
0.53
0.61
1.37
0.76
5.21
18.14
846
0.0
7.0
7.0
0.19
0.76
0.00
2.13
2.13
6.58
26.17
846
including
4.0
7.0
3.0
0.42
1.29
1.22
2.13
0.91
14.33
44.09
847
0.0
7.0
7.0
0.95
2.58
0.00
2.13
2.13
32.45
88.39
847
including
5.5
7.0
1.5
4.22
11.38
1.68
2.13
0.46
144.74
390.30
848
0.0
6.0
5.4
3.87
4.30
0.00
1.83
1.65
132.68
147.32
848
including
0.0
2.6
2.6
3.44
6.28
0.00
0.79
0.79
118.10
215.46
848
and
2.6
5.0
2.4
4.97
2.86
0.79
1.52
0.73
170.41
98.05
849
0.0
6.4
6.4
0.73
3.13
0.00
1.95
1.95
24.96
107.31
849
including
3.0
5.0
2.0
1.99
6.74
0.91
1.52
0.61
68.22
231.13
850
0.0
4.8
4.8
4.28
3.18
0.00
1.46
1.46
146.80
108.93
850
including
1.7
2.4
0.7
28.02
16.58
0.52
0.73
0.21
960.82
568.50
851
0.0
3.0
3.0
0.17
0.86
0.00
0.91
0.91
5.84
29.48
851
including
2.0
3.0
1.0
0.39
1.36
0.61
0.91
0.30
13.40
46.79
852
0.0
5.7
5.7
0.17
1.65
0.00
1.74
1.74
5.78
56.70
852
including
4.7
5.7
1.0
0.78
0.78
1.43
1.74
0.30
26.64
26.77
853
0.0
4.0
4.0
0.40
1.64
0.00
1.22
1.22
13.75
56.29
853
including
0.0
1.0
1.0
0.93
4.49
0.00
0.30
0.30
31.95
153.93
853
and
2.0
3.0
1.0
0.36
0.65
0.61
0.91
0.30
12.34
22.39
854
0.0
5.7
5.7
0.82
1.94
0.00
1.74
1.74
28.12
66.67
854
including
0.0
0.7
0.7
4.06
6.82
0.00
0.21
0.21
139.05
233.94
854
and
2.3
5.1
2.8
0.54
1.61
0.70
1.55
0.85
18.68
55.13
855
0.0
4.7
4.7
0.27
3.18
0.00
1.43
1.43
9.42
108.95
855
including
0.0
1.2
1.2
0.54
8.77
0.00
0.37
0.37
18.35
300.72
856
0.0
4.7
4.7
1.50
0.96
0.00
1.43
1.43
51.26
32.85
856
including
3.0
4.7
1.7
4.03
0.00
0.91
1.43
0.52
138.10
0.01
857
0.0
4.6
4.6
0.43
5.48
0.00
1.40
1.40
14.65
187.93
857
including
0.0
1.8
1.8
0.22
4.21
0.00
0.55
0.55
7.68
144.35
857
and
3.3
4.6
1.3
1.08
9.83
1.01
1.40
0.40
37.18
337.05
858
0.0
3.3
3.3
0.07
1.23
0.00
1.01
1.01
2.42
42.33
859
0.0
3.2
3.2
0.03
1.06
0.00
0.98
0.98
1.17
36.35
860
0.0
8.0
8.0
0.62
5.76
0.00
2.44
2.44
21.13
197.56
860
including
0.0
2.0
2.0
1.80
3.25
0.00
0.61
0.61
61.62
111.48
860
and
2.0
4.0
2.0
0.67
19.55
0.61
1.22
0.61
22.86
670.29
861
0.0
8.0
8.0
0.24
0.33
0.00
2.44
2.44
8.23
11.39
861
including
0.0
2.0
2.0
0.93
0.98
0.00
0.61
0.61
31.97
33.45
862
No significant assays
863
0.0
2.3
2.3
5.44
3.18
0.00
0.70
0.70
186.58
108.93
863
including
0.0
0.7
0.7
17.68
9.77
0.00
0.21
0.21
606.14
334.95
864
0.0
6.3
6.3
0.12
2.17
0.00
1.92
1.92
4.22
74.49
864
including
3.5
5.8
2.3
0.30
3.01
1.07
1.77
0.70
10.18
103.26
865
No significant assays
866
No significant assays
867
0.0
6.0
6.0
0.26
0.75
0.00
1.83
1.83
8.89
25.63
867
including
0.0
3.0
3.0
0.37
0.83
0.00
0.91
0.91
12.68
28.58
868
No significant assays
869
0.0
4.0
4.0
3.76
10.87
0.00
1.22
1.22
128.78
372.67
869
including
1.5
4.0
2.5
6.00
16.42
0.46
1.22
0.76
205.62
563.01
870
0.0
5.0
5.0
1.23
4.42
0.00
1.52
1.52
42.22
151.53
870
including
0.0
2.0
2.0
3.06
10.98
0.00
0.61
0.61
105.03
376.40
871
0.0
3.5
3.5
0.39
1.25
0.00
1.07
1.07
13.21
42.81
871
including
1.0
2.5
1.5
0.89
2.79
0.30
0.76
0.46
30.48
95.68
872
0.0
8.0
8.0
0.38
0.96
0.00
2.44
2.44
12.97
32.82
872
including
4.0
6.0
2.0
0.68
1.32
1.22
1.83
0.61
23.48
45.25
873
0.0
6.1
6.1
1.03
4.97
0.00
1.86
1.86
35.33
170.36
873
including
1.4
2.1
0.7
5.80
16.69
0.43
0.64
0.21
198.80
572.20
874
0.0
3.7
3.7
3.74
90.25
0.00
1.13
1.13
128.11
3,094.36
874
including
0.0
1.9
1.9
6.51
50.45
0.00
0.56
0.56
223.23
1,729.77
875
0.0
6.0
6.0
0.12
0.28
0.00
1.83
1.83
4.18
9.65
876
0.0
6.0
6.0
0.32
0.98
0.00
1.83
1.83
10.83
33.51
876
including
0.0
3.0
3.0
0.57
1.15
0.00
0.91
0.91
19.39
39.50
877
0.0
3.0
3.0
5.13
35.08
0.00
0.91
0.91
175.74
1,202.83
877
including
0.0
2.0
2.0
7.23
48.68
0.00
0.61
0.61
247.93
1,669.10
878
0.0
4.0
4.0
12.60
22.50
0.00
1.22
1.22
432.04
771.44
878
including
0.0
0.6
0.6
15.61
29.49
0.00
0.18
0.18
535.28
1,011.18
878
and
0.6
1.6
1.0
16.55
72.09
0.18
0.49
0.30
567.26
2,471.51
878
and
1.6
3.0
1.4
17.25
0.00
0.49
0.91
0.43
591.50
0.01
879
0.0
4.4
4.4
5.33
2.63
0.00
1.34
1.34
182.61
90.14
879
including
0.0
1.6
1.6
14.43
5.97
0.00
0.49
0.49
494.63
204.62
880
No significant assays
881
0.0
4.8
4.8
0.05
0.27
0.00
1.46
1.46
1.72
9.34
881
including
0.0
1.0
1.0
0.19
0.90
0.00
0.30
0.30
6.51
30.75
882
0.0
8.0
8.0
0.24
0.63
0.00
2.44
2.44
8.39
21.76
882
including
4.0
6.0
2.0
0.51
0.69
1.22
1.83
0.61
17.45
23.79
883
No significant assays
884
0.0
6.0
6.0
0.37
2.37
0.00
1.83
1.83
12.64
81.22
884
including
0.0
3.0
3.0
0.49
4.32
0.00
0.91
0.91
16.80
147.99
885
0.0
4.0
4.0
0.26
3.62
0.00
1.22
1.22
8.77
124.11
885
including
1.0
2.0
1.0
0.31
2.62
0.30
0.61
0.30
10.66
89.86
885
and
3.0
4.0
1.0
0.48
8.37
0.91
1.22
0.30
16.44
286.81
886
No significant assays
887
0.0
6.7
6.7
4.25
18.95
0.00
2.04
2.04
145.78
649.80
887
including
2.8
4.0
1.2
17.81
46.14
0.85
1.22
0.37
610.55
1,581.85
889
0.0
12.0
12.0
4.62
6.95
0.00
3.66
3.66
158.23
238.30
889
including
0.0
2.0
2.0
2.65
1.83
0.00
0.61
0.61
90.81
62.70
889
and
4.0
6.0
2.0
13.56
15.34
1.22
1.83
0.61
464.83
525.95
889
and
6.0
8.0
2.0
9.56
20.49
1.83
2.44
0.61
327.84
702.40
889
and
8.0
10.0
2.0
0.69
1.91
2.44
3.05
0.61
23.65
65.55
889
and
10.0
12.0
2.0
0.91
1.42
3.05
3.66
0.61
31.33
48.71
890
No significant assays
891
No significant assays
892
No significant assays
893
0.0
6.4
6.4
20.26
15.76
0.00
1.95
1.95
694.50
540.37
893
including
0.0
3.5
3.5
2.60
5.47
0.00
1.07
1.07
89.06
187.48
893
and
3.5
4.6
1.1
108.57
71.60
1.07
1.40
0.34
3,722.31
2,454.88
894
No significant assays
895
0.0
10.0
10.0
0.05
0.24
0.00
3.05
3.05
1.67
8.40
895
including
0.0
2.0
2.0
0.21
1.05
0.00
0.61
0.61
7.31
35.83
896
0.0
4.5
4.5
80.85
66.20
0.00
1.37
1.37
2,771.97
2,269.69
896
including
1.0
3.3
2.3
157.23
128.17
0.30
1.01
0.70
5,390.78
4,394.48
898
0.0
5.5
5.5
11.97
17.20
0.00
1.68
1.68
410.31
589.75
898
including
3.0
4.5
1.5
41.72
59.72
0.91
1.37
0.46
1,430.44
2,047.51
898
and
4.5
5.5
1.0
2.95
4.99
1.37
1.68
0.30
101.17
171.13
899
0.0
1.8
1.8
2.16
1.40
0.00
0.55
0.55
73.96
48.00
899
including
1.3
1.8
0.5
7.63
4.75
0.40
0.55
0.15
261.43
163.01
900
0.0
1.4
1.4
0.65
6.07
0.00
0.43
0.43
22.42
208.16
901
0.0
2.0
2.0
1.25
4.38
0.00
0.61
0.61
42.96
150.09
902
No significant assays
903
No significant assays
904
No significant assays
905
0.0
12.0
12.0
0.21
0.71
0.00
3.66
3.66
7.24
24.37
905
including
0.0
3.0
3.0
0.72
1.63
0.00
0.91
0.91
24.56
55.81
906
0.0
12.0
12.0
1.33
3.10
0.00
3.66
3.66
45.58
106.23
906
including
3.0
6.0
3.0
2.40
6.86
0.91
1.83
0.91
82.21
235.04
906
and
9.0
12.0
3.0
2.11
3.63
2.74
3.66
0.91
72.40
124.37
907
No significant assays
908
No significant assays
909
0.0
5.0
5.0
0.55
0.82
0.00
1.52
1.52
18.73
28.27
909
including
0.0
1.6
1.6
0.57
0.71
0.00
0.49
0.49
19.63
24.19
909
and
1.6
3.0
1.4
1.30
1.73
0.49
0.91
0.43
44.44
59.19
910
0.0
5.0
5.0
17.70
7.11
0.00
1.52
1.52
606.75
243.87
910
including
0.0
2.0
2.0
12.55
6.64
0.00
0.61
0.61
430.14
227.71
910
and
2.0
3.0
1.0
51.03
13.35
0.61
0.91
0.30
1,749.76
457.69
910
and
3.0
5.0
2.0
6.18
4.47
0.91
1.52
0.61
211.86
153.12
911
0.0
4.0
4.0
33.61
6.25
0.00
1.22
1.22
1,152.40
214.18
911
including
1.0
2.0
1.0
121.05
12.42
0.30
0.61
0.30
4,150.15
425.99
911
and
2.0
4.0
2.0
6.58
5.98
0.61
1.22
0.61
225.55
205.14
912
0.0
8.0
8.0
0.10
0.50
0.00
2.44
2.44
3.41
17.12
912
including
0.0
2.0
2.0
0.37
0.75
0.00
0.61
0.61
12.75
25.74
913
0.0
5.5
5.5
79.45
6.27
0.00
1.68
1.68
2,724.03
215.12
913
including
1.8
2.8
1.0
434.09
33.65
0.55
0.85
0.30
14,883.20
1,153.72
914
0.0
5.0
5.0
16.63
2.49
0.00
1.52
1.52
570.32
85.46
914
including
0.0
2.0
2.0
26.47
3.86
0.00
0.61
0.61
907.44
132.26
914
and
2.0
3.0
1.0
24.70
2.38
0.61
0.91
0.30
846.79
81.52
914
and
3.0
5.0
2.0
2.77
1.18
0.91
1.52
0.61
94.96
40.62
915
No significant assays
916
0.0
20.0
20.0
0.17
32.70
0.00
6.10
6.10
5.66
1,121.28
916
including
4.0
6.0
2.0
0.83
1.42
1.22
1.83
0.61
28.36
48.73
916
and
16.0
18.0
2.0
0.20
322.38
4.88
5.49
0.61
7.01
11,053.15
917
0.0
4.5
4.5
3.40
5.03
0.00
1.37
1.37
116.71
172.46
917
including
0.0
1.3
1.3
2.89
1.56
0.00
0.40
0.40
98.93
53.44
917
and
1.3
2.6
1.3
8.47
14.44
0.40
0.79
0.40
290.57
495.25
918
0.0
20.0
20.0
0.23
1.55
0.00
6.10
6.10
7.78
53.15
918
including
2.0
4.0
2.0
1.24
2.52
0.61
1.22
0.61
42.45
86.47
919
0.0
12.0
12.0
0.16
4.41
0.00
3.66
3.66
5.65
151.22
919
including
10.0
12.0
2.0
0.47
3.04
3.05
3.66
0.61
16.23
104.22
920
0.0
12.0
12.0
0.06
1.22
0.00
3.66
3.66
2.16
41.67
921
0.0
4.0
4.0
0.57
1.87
0.00
1.22
1.22
19.49
63.96
921
including
1.6
3.3
1.7
1.31
4.30
0.49
1.01
0.52
44.81
147.42
922
0.0
4.9
4.9
0.33
0.39
0.00
1.49
1.49
11.45
13.23
922
including
0.0
2.2
2.2
0.47
0.31
0.00
0.67
0.67
16.21
10.69
922
and
2.2
3.2
1.0
0.57
0.98
0.67
0.98
0.30
19.57
33.45
923
No significant assays
924
0.0
3.8
3.8
0.31
0.57
0.00
1.16
1.16
10.61
19.64
924
including
1.4
2.2
0.8
1.45
2.67
0.43
0.67
0.24
49.55
91.54
925
0.0
16.0
16.0
0.13
2.71
0.00
4.88
4.88
4.53
93.08
925
including
10.0
12.0
2.0
0.72
14.77
3.05
3.66
0.61
24.72
506.27
926
0.0
16.0
16.0
0.21
2.17
0.00
4.88
4.88
7.04
74.45
926
including
4.0
6.0
2.0
0.66
7.21
1.22
1.83
0.61
22.76
247.31
926
and
10.0
12.0
2.0
0.36
0.64
3.05
3.66
0.61
12.51
21.80
927
0.0
5.3
5.3
2.83
1.40
0.00
1.62
1.62
97.18
48.12
927
0.8
1.8
1.0
14.57
7.44
0.24
0.55
0.30
499.55
254.97
928
No significant assays
0.00
0.00
0.00
0.00
0.00
929
0.0
4.0
4.0
0.23
0.50
0.00
1.22
1.22
8.01
17.07
929
including
0.0
3.0
3.0
0.31
0.66
0.00
0.91
0.91
10.63
22.76
930
0.0
90.0
90.0
0.06
0.72
0.00
27.43
27.43
2.17
24.53
930
including
25.0
30.0
5.0
0.29
0.00
7.62
9.14
1.52
10.11
0.01
930
and
55.0
60.0
5.0
0.43
10.19
16.76
18.29
1.52
14.67
349.50
931
No significant assays
932
No significant assays
933
No significant assays
934
0.0
6.0
6.0
0.02
0.31
0.00
1.83
1.83
0.75
10.58